A case in which the performance status was maintained by jejunostomy for unresectable gastric cancer with obstruction-Reference-Cited by-同舟云学术

A case in which the performance status was maintained by jejunostomy for unresectable gastric cancer with obstruction

Published:2019 Issue:2 Volume:53 Page:111-117
ISSN:0389-5564
Container-title:The Japanese Journal of SURGICAL METABOLISM and NUTRITION
language:en
Short-container-title:

Author:

Kambe Kosuke¹,Nagata Tomoyuki²,Tamai Mizuki²,Kamiya Hajime²,Taniguchi Akihiro¹,Kamada Yosuke²,Fukuda Ken-ichiro²,Iwata George¹,Yamaoka Nobuki²,Thukamoto Kenji²

Affiliation:

1. Kyoto Chubu Medical Center Pediatric Surgery

2. Kyoto Chubu Medical Center Surgery

Publisher

Japanese Society for Surgical Metabolism and Nutrition

Link

https://www.jstage.jst.go.jp/article/jssmn/53/2/53_111/_pdf

Reference8 articles.

1. 1) Boku N, Yamamoto S, Fukuda H et al.: Fluorouracil versus combination of irinotecan plus cisplatin versus S‐1 in metastatic gastric cancer : a randomised phase 3 study. Lancet Oncol 10: 1063‐1069, 2009

2. 2) Boku N, Yamamoto S, Shirao T et al.: Random ized Phase III study of 5‐fluorouracil alone versus combination of irinotecan and cisplatin versus S‐1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol 25: 200, 2007

3. 3) Koizumi W, Narahara H, Hara T et al.: S‐1 plus cisplatin versus S‐1 alone for the first‐line treatment of advanced gastric cancer (SPIRITS trial) a phase III trial. Lancet Oncol 9, 215‐221, 2008

4. 4) Climent M, Munarriz, Blazeby JM et al.: Weight loss and quality of life in patients surviving 2 years after gastric cancer resection. Eur J Surg Oncol 43: 1337‐1343, 2017

5. 5) Yamaoka Y, Fujitani K, Tsujinaka T et al.: Skeletal muscle loss after total gastrectomy, exacerbated by adjuvant chemotherapy. Gastric Cancer 18: 382‐389, 2015